Company Profile:
ONKO ILAC SAN VE TIC A.S. is a factory (manufacturer).
Company Introduction for ONKO ILAC SAN VE TIC A.S.
ONKO ILAC SAN VE TIC A.S. is a prominent Turkish pharmaceutical company established with a strong focus on oncology. Based in Gebze, Kocaeli, Turkey, the company is dedicated to the research, development, manufacturing, and marketing of high-quality and accessible pharmaceutical products, primarily in the field of cancer treatment.
As a manufacturer, ONKO ILAC operates modern production facilities equipped with advanced technology, adhering to international quality standards such as Good Manufacturing Practices (GMP). Their core mission is to contribute to improving the quality of life for cancer patients by providing innovative, effective, and reliable therapeutic solutions. The company invests significantly in research and development to bring new and improved treatments to the market, addressing critical needs in oncology.
Enterprise Products
ONKO ILAC SAN VE TIC A.S. primarily manufactures and sells pharmaceutical products with a significant focus on oncology, hematology, and supportive care.
Their product portfolio includes:
Oncology products: This category encompasses a wide range of chemotherapeutic agents (such as Paclitaxel, Docetaxel, Gemcitabine, Carboplatin, Cisplatin, Oxaliplatin, Irinotecan, Pemetrexed, Capecitabine, Etoposide, Cyclophosphamide, Ifosfamide, Methotrexate, Doxorubicin, Daunorubicin, Bleomycin, Vincristine, Vinblastine), targeted therapies (including Erlotinib, Lapatinib, Sunitinib, Sorafenib, Imatinib, Nilotinib, Dasatinib, Everolimus, Lenalidomide, Pomalidomide), and hormonal therapies (like Letrozole, Anastrozole, Exemestane, Tamoxifen, Bicalutamide, Flutamide, Goserelin, Leuprolide) used in the treatment of various cancers.
Hematology products: These include treatments for blood disorders, lymphomas, leukemias, and multiple myeloma, as well as growth factors such as Filgrastim, Pegfilgrastim, and Epoetin alfa.
Supportive care products: This segment offers medications designed to manage the side effects of cancer treatments and improve patient quality of life. Examples include anti-emetics (such as Ondansetron, Granisetron, Aprepitant) and bone health agents (like Zoledronic acid, Denosumab).